Rotating Boulder, a fund management company, Walvax, a biological pharmaceutical enterprise, and Riverhead Capital, a private equity fund management firm, led a $105m Series D funding round in Sirnaomics, a clinical stage biopharma company. The round was also joined by Longmen Capital, HongTao Capital and Alpha Win Capital. Proceeds for the financing will be used to fund continued development of its novel RNAi therapeutics for treatment of diverse human disorders, including cancers, fibrosis diseases, metabolic diseases and viral infections. "We are very excited to get the D round of financing closed in a timely manner. The fact that the D round was oversubscribed is further validation that RNAi therapeutics are attracting a great deal of interest from the investment community and is fuelled by innovative targeted technologies and very impressive clinical results. We are thrilled to add a well-regarded syndicate of investors to the Series D financing. This type of investor base will not only strengthen our financial foundation, but also brings tremendous experience and expertise to Sirnaomics as it enters the next phase of growth and prepares for an initial public offering in near future," Patrick Lu, Sirnaomics Founder, President and CEO.